Genotypes

2009

Back to Main Genotype Page

All About Genotype

Geno 1 HCV Patients Low Viral Load Can Achieve SVR 24wks with Pegylated Interferon and Ribavirin

Nov 16

More Than 80 Percent of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen

Nov 01

HCV Genotype 3 May Be Associated with More Rapid Liver Fibrosis Progression in People with Chronic Hepatitis C

Normal Liver Enzymes In: HCV/HBV/Fatty Liver

Oct 27

Albinterferon-α-2b in Patients with Genotype 2/3 Chronic Hepatitis C

Oct 5

Treatment of Hepatitis C Genotype 1 Infected Patients (Video)

Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes Sep 01

Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection: genotype 1 can achieve high SVR rate is treated during acute infection - (08/20/09)

Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients with the Protease Inhibitor Telaprevir

Aug 09

Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin

July 09

Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6

: BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naïve and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain

June 09

Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy

Telaprevir Effective for Genotype 2 But Not For Genotype 3

Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients

Dr. Kuemmerle, Dr. Emmet Keeffe and Dr. Michael W. Fried discuss study results that show the combination of nitazoxanide, peginterferon alfa-2a, and ribavirin improved percentages of patients with rapid virologic response (RVR) and sustained virologic response (SVR).

Rossignol JF, Elfert A, El–Gohary Y, et al.  Improved Virologic Response in Chronic Hepatitis C 136: 856-862
http://www.gastrojournal.org/article/S0016-5085(08)02051-9/abstract

EXTENDED TREATMENT DURATION TO 72 Weeks IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY (SUCCESS) -

EASL: BASELINE CHARACTERISTICS AND WEEK 4 RESPONSE AMONG CHRONIC HEPATITIS C PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 OR 4: INTERIM RESULTS OF THE PROPHESYS TRIAL - (05/13/09)

EASL: Identifying Patients Infected With HCV Genotype 1 Who May Benefit From Extended Peginterferon Alfa-2a/Ribavirin Therapy Beyond 48 Weeks - (05/13/09)

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection...PROVE1 in NEJM 4/2009 - (05/08/09) 

EASL: Albuferon vs Pegasys Genotype 2/3 - (05/07/09)

EASL: Albuferon vs Pegasys Genotype 1 - (05/07/09)

EASL: Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide with Peginterferon Alfa-2a and Ribavirin in Nonresponders (NR) with Chronic HCV Genotype 1: Week 28 Interim Analysis - (05/07/09)

EASL: Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Interim Analysis Shows Increase in EVR - (05/07/09)

EASL: Abbott/Enanta - Potent HCV Protease Inhibitors with the Potential for Once-daily Dosing and Broad Genotype Coverage - (05/05/09)

 EASL: 2 Schering HCV Protease Inhibitors; Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

EASL: EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS

EASL: SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS

EASL: Potent Antiviral Activity With A Nucleoside Polymerase (R7128) And Protease (R7227/ITMN-191) Inhibitor Combination in HCV Genotype 1: Initial Safety, Pharmacokinetics, And Virologic Results From INFORM-1 - (04/28/09)

TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY

Antiviral Activity of Filibuvir in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days in Treatment-Naive Patients Chronically Infected with HCV Genotype 1

Antiviral activity and safety of TMC435 combined with peginterferon a-2a and ribavirin in patients with genotype-1 hepatitis C infection who failed previous IFN-based therapy -

2 Schering HCV Protease Inhibitors; Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

Nitazoxanide Added to Treatment of Hepatitis C Genotype 4 Improves Outcome

Early Changes in Hepatitis C Virus (HCV) Levels in Response to Peginterferon and Ribavirin Treatment in Patients with Chronic HCV Genotype 1 Infection

Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b

STAT-C Resistance Geno 1 and High Viral Load

Early Discontinuation of Ribavirin May Be Appropriate for Selected Genotype 2 or 3 Chronic Hepatitis C Patients

Liver Disease Progression and Treatment Response in 90% Geno 1 Latino and Asian Patients with Chronic Hepatitis C

Hepatitis C Genotype Guides Health Plans

Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS((R))) plus ribavirin (COPEGUS((R))) for 16 or 24 weeks

Updated Information on Treatment According to Genotype:

 2008   2007   2006

2005 Index  Genotype Research  /  2004 Thru 2001 Index of all Genotype Research